News Bristol-Myers Squibb Company Buenos Aires S.E.

Equities

BMY

ARDEUT112877

End-of-day quote Buenos Aires S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
19,250 ^ARS	+0.52%		+4.33%	+16.98%

Jul. 12	UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	MT
Jul. 11	Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	Jul. 12	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	Jul. 11	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43	Jul. 10	MT
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day	Jul. 08	BU
Ex-dividend day	Jul. 04	FA
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	Jul. 02	CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	Jul. 01	MT
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America	Jul. 01	AQ
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin	Jul. 01	CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	Jun. 27	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	Jun. 26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	Jun. 26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	Jun. 26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	Jun. 26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	Jun. 26	MT
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	Jun. 24	AQ
Bristol Myers: accelerated approval in colorectal cancer	Jun. 24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	Jun. 21	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Jun. 21	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	Jun. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST